GlassScriptPhysician profile
Kimberly Oosterom
NPI 1568805935
$4,409.31
in general payments reported to CMS, 2019-2025
25 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,103 · 2022: $770 · 2023: $667 · 2024: $1,466 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $729.02 | 2021-2024 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.61 | 2021-2025 | Jardiance |
| Amgen INC. | $474.15 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $469.21 | 2021-2024 | |
| Novo Nordisk INC | $432.73 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $288.33 | 2024-2025 | Verquvo, Gardasil 9, Gardasil |
| Lilly USA, LLC | $276.77 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Atricure, INC. | $215.40 | 2024 | |
| Janssen Pharmaceuticals, INC | $166.12 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $151.19 | 2021-2025 | Farxiga, Lokelma |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Pfizer INC. | $73.19 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $68.11 | 2024 | Voquezna |
| Ardelyx, INC. | $53.86 | 2024 | Ibsrela |
| Esperion Therapeutics, INC. | $53.44 | 2024 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $44.58 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.66 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $23.50 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $22.54 | 2023 | Livalo |
| Medicomp INC | $21.97 | 2022 | |
| Glaxosmithkline, LLC. | $19.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.52 | 2024 | Entyvio |
| Abbvie INC. | $18.48 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.77 | 2021 | |
| Amarin Pharma, INC. | $12.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Oosterom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.